Deyaa Adib, MD, on Safety Advantages of TAC T-Cell Therapy in Solid Tumors


The chief medical officer of Triumvira Immunologics discussed how TAC01-HER2 could address unmet needs in treating solid tumors.

"The most valuable advantage we see so far would be the safety profile associated with HER2-TAC T-cells and it is very well differentiated thus far compared to approved CARs. So far we have not seen any dose limiting toxicities, cytokine release syndrome, or neurotoxicity in dose levels 1 and 2."

Triumvira Immunologics’ TAC01-HER2, a HER2-targeted T-cell antigen coupler (TAC) T-cell therapy, was well-tolerated with early signs of clinical activity. In new data from cohort 2 of the phase 1/2 TACTIC-2 study, the therapy yielded a partial response in a patient with stage 4b gastric cancer and a 75% disease control rate.

Data from the study were presented by Benjamin L. Schlechter, MD, instructor, medicine, Harvard Medical School, and Dana-Farber Cancer Institute, at the European Society for Medical Oncology (ESMO) Congress 2022, held September 9-13, in Paris, France. The trial will be enrolling in its phase 2 portion in the beginning of 2023.

CGTLive spoke with senior author Deyaa Adib, MD, chief medical officer, Triumvira Immunologics, to learn more about unmet needs in patients with solid tumors. He discussed the advantages of the TAC T-cell technology in addressing these unmet needs, including a positive safety profile with lower rates of cytokine release syndrome compared to those seen in other cell therapy trials.

Click here to read more coverage of ESMO Congress 2022.

Schlechter BL, Ileana Dumbrava EE, Olson D, et al. A phase I/II trial investigating safety and efficacy of autologous TAC T-cells targeting HER2 in relapsed or refractory solid tumors. Presented at: ESMO Congress 2022, September 9-13, Paris, France. Poster #778TiP
Related Videos
Janice Chen, PhD, the cofounder and chief technology officer of Mammoth Biosciences
Sekar Kethiresan, MD, on Following up VERVE-101 With Next-Generation Editing Therapies
Maria Escolar, MD, the chief medical officer of Forge Biologics
Leigh Ramos-Platt, MD, on Allowing Access and Ensuring Preparation for Gene Therapies
John Murphy, PhD, the chief scientific officer of Arbor Biotechnologies
Erika Fullwood Augustine, MD, MS, the associate chief science officer of the Kennedy Krieger Institute
Maria Escolar, MD, the chief medical officer of Forge Biologics
Casey Maguire, PhD, associate professor of neurology and associate investigator of neurology, Harvard Medical School
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics
© 2024 MJH Life Sciences

All rights reserved.